You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《新股消息》瑞科生物-B(02179.HK)公開發售超購9.7倍 一手中籤率9.3%
阿思達克 03-30 10:24
瑞科生物-B(02179.HK)公布招股結果,每股發售價定為24.8元,與招股價相同,香港公開發售部分錄得超額認購約9.65倍,每手500股計,一手中籤率為9.28%,要認購12手即6,000股才穩獲一手。該股將於明日(31日)掛牌。聯席保薦人為摩根士丹利、招銀國際及中信証券。 基石投資者包括揚子江香港、Harvest、SCHP及紅杉資本中國轄下Sequoia Capital China Growth,合共認購公司1,671.85萬股,佔緊隨全球發售完成後已發行H股約18.62%,佔緊隨全球發售完成後所有權約3.49%。 公司是次上市料淨集約6.72億元,約47.3%將分配予公司HPV疫苗管線(包括核心產品,即REC603)的研發、生產及商業化;17.7%將分配予新冠肺炎候選疫苗ReCOV;21.1%將分配至其他候選疫苗(包括結核病疫苗REC606及REC607、重組四價流感疫苗REC617及重組手足口病四價疫苗REC605等)的臨床前及臨床研究、註冊;6.7%將分配至進一步加強研發能力及提高營運效率;7.2%用於營運資金及其他一般公司用途。
Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account